Cargando…

Five-Year Outcome of Aflibercept Monotherapy for Exudative Age-Related Macular Degeneration with Good Baseline Visual Acuity

We investigated the long-term visual and anatomical outcomes of aflibercept monotherapy for exudative age-related macular degeneration (AMD) with good baseline best-corrected visual acuity (BCVA). A medical chart review was performed for 40 consecutive patients with baseline decimal BCVA ≥ 0.6 secon...

Descripción completa

Detalles Bibliográficos
Autores principales: Kikushima, Wataru, Sakurada, Yoichi, Sugiyama, Atsushi, Yoneyama, Seigo, Matsubara, Mio, Fukuda, Yoshiko, Kashiwagi, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961756/
https://www.ncbi.nlm.nih.gov/pubmed/33807964
http://dx.doi.org/10.3390/jcm10051098
_version_ 1783665330854297600
author Kikushima, Wataru
Sakurada, Yoichi
Sugiyama, Atsushi
Yoneyama, Seigo
Matsubara, Mio
Fukuda, Yoshiko
Kashiwagi, Kenji
author_facet Kikushima, Wataru
Sakurada, Yoichi
Sugiyama, Atsushi
Yoneyama, Seigo
Matsubara, Mio
Fukuda, Yoshiko
Kashiwagi, Kenji
author_sort Kikushima, Wataru
collection PubMed
description We investigated the long-term visual and anatomical outcomes of aflibercept monotherapy for exudative age-related macular degeneration (AMD) with good baseline best-corrected visual acuity (BCVA). A medical chart review was performed for 40 consecutive patients with baseline decimal BCVA ≥ 0.6 secondary to exudative AMD. Three monthly injections were administrated, and thereafter additional injection was performed if needed over 5 years. In total, 13 eyes with neovascular AMD (nAMD) and 27 eyes with polypoidal choroidal vasculopathy (PCV) were enrolled. In both groups, the mean BCVA significantly improved at the 12-month visit (p < 0.05). However, the significant improvement in BCVA disappeared at the 24-month visit, and the final mean BCVA was equivalent to that at baseline (p = 0.17 in the nAMD group and p = 0.15 in the PCV group). The median number of injections required after the loading dose was 15.0 during the 5-year follow-up (nAMD:15.0 vs. PCV:15). During the study period, 37 (92.5%) eyes required retreatment(s). Cox regression analysis demonstrated that the protective allele of ARMS2 A69S was associated with a retreatment-free period from the initial injection (p = 0.041, repeated forward selection method). As-needed aflibercept monotherapy is a preferable treatment option for exudative AMD with good initial visual acuity regardless of nAMD or PCV during the 5-year study period.
format Online
Article
Text
id pubmed-7961756
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79617562021-03-17 Five-Year Outcome of Aflibercept Monotherapy for Exudative Age-Related Macular Degeneration with Good Baseline Visual Acuity Kikushima, Wataru Sakurada, Yoichi Sugiyama, Atsushi Yoneyama, Seigo Matsubara, Mio Fukuda, Yoshiko Kashiwagi, Kenji J Clin Med Article We investigated the long-term visual and anatomical outcomes of aflibercept monotherapy for exudative age-related macular degeneration (AMD) with good baseline best-corrected visual acuity (BCVA). A medical chart review was performed for 40 consecutive patients with baseline decimal BCVA ≥ 0.6 secondary to exudative AMD. Three monthly injections were administrated, and thereafter additional injection was performed if needed over 5 years. In total, 13 eyes with neovascular AMD (nAMD) and 27 eyes with polypoidal choroidal vasculopathy (PCV) were enrolled. In both groups, the mean BCVA significantly improved at the 12-month visit (p < 0.05). However, the significant improvement in BCVA disappeared at the 24-month visit, and the final mean BCVA was equivalent to that at baseline (p = 0.17 in the nAMD group and p = 0.15 in the PCV group). The median number of injections required after the loading dose was 15.0 during the 5-year follow-up (nAMD:15.0 vs. PCV:15). During the study period, 37 (92.5%) eyes required retreatment(s). Cox regression analysis demonstrated that the protective allele of ARMS2 A69S was associated with a retreatment-free period from the initial injection (p = 0.041, repeated forward selection method). As-needed aflibercept monotherapy is a preferable treatment option for exudative AMD with good initial visual acuity regardless of nAMD or PCV during the 5-year study period. MDPI 2021-03-05 /pmc/articles/PMC7961756/ /pubmed/33807964 http://dx.doi.org/10.3390/jcm10051098 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kikushima, Wataru
Sakurada, Yoichi
Sugiyama, Atsushi
Yoneyama, Seigo
Matsubara, Mio
Fukuda, Yoshiko
Kashiwagi, Kenji
Five-Year Outcome of Aflibercept Monotherapy for Exudative Age-Related Macular Degeneration with Good Baseline Visual Acuity
title Five-Year Outcome of Aflibercept Monotherapy for Exudative Age-Related Macular Degeneration with Good Baseline Visual Acuity
title_full Five-Year Outcome of Aflibercept Monotherapy for Exudative Age-Related Macular Degeneration with Good Baseline Visual Acuity
title_fullStr Five-Year Outcome of Aflibercept Monotherapy for Exudative Age-Related Macular Degeneration with Good Baseline Visual Acuity
title_full_unstemmed Five-Year Outcome of Aflibercept Monotherapy for Exudative Age-Related Macular Degeneration with Good Baseline Visual Acuity
title_short Five-Year Outcome of Aflibercept Monotherapy for Exudative Age-Related Macular Degeneration with Good Baseline Visual Acuity
title_sort five-year outcome of aflibercept monotherapy for exudative age-related macular degeneration with good baseline visual acuity
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961756/
https://www.ncbi.nlm.nih.gov/pubmed/33807964
http://dx.doi.org/10.3390/jcm10051098
work_keys_str_mv AT kikushimawataru fiveyearoutcomeofafliberceptmonotherapyforexudativeagerelatedmaculardegenerationwithgoodbaselinevisualacuity
AT sakuradayoichi fiveyearoutcomeofafliberceptmonotherapyforexudativeagerelatedmaculardegenerationwithgoodbaselinevisualacuity
AT sugiyamaatsushi fiveyearoutcomeofafliberceptmonotherapyforexudativeagerelatedmaculardegenerationwithgoodbaselinevisualacuity
AT yoneyamaseigo fiveyearoutcomeofafliberceptmonotherapyforexudativeagerelatedmaculardegenerationwithgoodbaselinevisualacuity
AT matsubaramio fiveyearoutcomeofafliberceptmonotherapyforexudativeagerelatedmaculardegenerationwithgoodbaselinevisualacuity
AT fukudayoshiko fiveyearoutcomeofafliberceptmonotherapyforexudativeagerelatedmaculardegenerationwithgoodbaselinevisualacuity
AT kashiwagikenji fiveyearoutcomeofafliberceptmonotherapyforexudativeagerelatedmaculardegenerationwithgoodbaselinevisualacuity